Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Mark A Wainberg"'
Autor:
Anita Rachlis, Marianne Harris, Richard Lalonde, Stephen D Shafran, Cécile Tremblay, Mark A Wainberg, Sharon Walmsley
Publikováno v:
Canadian Journal of Infectious Diseases and Medical Microbiology, Vol 21, Iss 4, Pp 159-172 (2010)
BACKGROUND AND OBJECTIVES: A Canadian group, consisting of six physicians and an HIV researcher with significant experience and knowledge in HIV management, reviewed the available data and developed guidelines for Canadian health care providers (who
Externí odkaz:
https://doaj.org/article/29af8fad739743de85d6ffd669937723
Autor:
Anita Rachlis, Jonathan B Angel, Marianne Harris, Stephen D Shafran, Rachel Therrien, Cécile Tremblay, Mark A Wainberg
Publikováno v:
Canadian Journal of Infectious Diseases and Medical Microbiology, Vol 20, Iss 3, Pp e67-e80 (2009)
BACKGROUND AND OBJECTIVES: A meeting of a Canadian group with significant experience and knowledge in HIV management, consisting of five physicians, a pharmacist and an AIDS researcher, was convened. Their goal was to develop guidance for Canadian HI
Externí odkaz:
https://doaj.org/article/0653f2f65e0b4f96aa6ea842cabf811d
Publikováno v:
Infection, Genetics and Evolution. 46:286-291
Three integrase strand transfer inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG), have been approved by the FDA. Resistance against these three INSTIs have been reported and cross-resistance among them has been docume
Autor:
Jing Leng, Mark A. Wainberg, Hanh T. Pham, Yudong Quan, Thibault Mesplède, Jiaming Liang, Ying-Shan Han
Publikováno v:
mBio, Vol 9, Iss 5 (2018)
mBio, Vol 9, Iss 5, p e01450-18 (2018)
mBio, Vol 9, Iss 5, p e01450-18 (2018)
Volume 8, no. 2, e00157-17, 2017, [https://doi.org/10.1128/mBio.00157-17][1]. One source of funding for our study was not properly acknowledged. The acknowledgment section of the manuscript should read: We regret to note that Mark A. Wainberg passed
Publikováno v:
Journal of Virology. 92
Integrase strand transfer inhibitors (INSTIs) are the newest class of antiretrovirals to be approved for the treatment of HIV infection. Canonical resistance to these competitive inhibitors develops through substitutions in the integrase active site
Autor:
Daniela Moisi, Peter K. Quashie, Mark A. Wainberg, Thibault Mesplède, Yannan Liu, Maureen Oliveira, Said Hassounah, Bluma G. Brenner, Paul Sandstrom
Publikováno v:
Journal of Virology. 89:12002-12013
We previously showed that the simian immunodeficiency virus SIVmac239 is susceptible to human immunodeficiency virus (HIV) integrase (IN) strand transfer inhibitors (INSTIs) and that the same IN drug resistance mutations result in similar phenotypes
Publikováno v:
Future Microbiology. 10:1773-1782
Inhibitors that target the retroviral enzyme reverse transcriptase (RT) have played an indispensable role in the treatment and prevention of HIV-1 infection. They can be grouped into two distinct therapeutic groups, namely the nucleoside and nucleoti
Integrase strand transfer inhibitors (INSTIs) are the newest class of antiretrovirals to be approved for the treatment of HIV infection. Canonical resistance to these competitive inhibitors develops through substitutions in the integrase active site
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e891e578b62b4218a96d32bdcc5ff37f
https://europepmc.org/articles/PMC5640858/
https://europepmc.org/articles/PMC5640858/
Publikováno v:
Journal of Virology. 89:4681-4684
The new integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) displays limited cross-resistance with older drugs of this class and selects for the R263K substitution in treatment-experienced patients. We performed tissue culture selections w
Autor:
Tamar Veres, Maureen Oliviera, Said Hassounah, Yolanda Lie, Wei Huang, Ying-Shan Han, Mark A. Wainberg, Peter K. Quashie, Thibault Mesplède, Nathan Osman
Publikováno v:
Journal of Virology. 89:3163-3175
Dolutegravir (DTG) is the latest antiretroviral (ARV) approved for the treatment of human immunodeficiency virus (HIV) infection. The G118R substitution, previously identified with MK-2048 and raltegravir, may represent the initial substitution in a